Tugce batur

Dr. Tugce batur

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
HYHuriye Erbak Yilmaz
Huriye Erbak Yilmaz
EIEvin Iscan
Evin Iscan
OOOzden Oz
Ozden Oz
TBTugce batur
Tugce batur
AEAybike Erdoğan
Aybike Erdoğan
KSKevin Spring
Kevin Spring

Verified
Journal Article
Open access
PDF file
TBTugce batur
Tugce batur
AAAYSE ARGÜNDOĞAN
AYSE ARGÜNDOĞAN
UKUmur Keles
Umur Keles
ZMZeynep Mutlu
Zeynep Mutlu
HAHani Alotaibi
Hani Alotaibi
MOMehmet Ozturk
Mehmet Ozturk
AXL, a member of the TAM family, is a promising therapeutic target due to its elevated expression in advanced hepatocellular carcinoma (HCC), particularly in association with acquired drug resistance. Previously, RNA interference was used to study its role in cancer, and several phenotypic changes, including attenuated cell proliferation and decreased migration and invasion, have been reported. The mechanism of action of AXL in HCC is elusive. We first studied the AXL expression in HCC cell lines by real-time PCR and western blot and showed its stringent association with a mesenchymal phenotype. We then explored the role of AXL in mesenchymal SNU475 cells by CRISPR-Cas9 mediated gene knock-out. AXL-depleted HCC cells displayed drastic phenotypic changes, including increased DNA damage response, prolongation of doubling time, G2 arrest, and polyploidization in vitro and loss of tumorigenicity in vivo. Pharmacological inhibition of AXL by R428 recapitulated G2 arrest and polyploidy phenotype. These observations strongly suggest that acute loss of AXL in some mesenchymal HCC cells is lethal and points out that its inhibition may represent a druggable vulnerability in AXL-high HCC patients.

17 February 2026 in The FEBS Journal
Verified
Journal Article
Closed access
ESEsin Ozkuru Sekeroglu
Esin Ozkuru Sekeroglu
ŞYŞeyma N. Yıldız
Şeyma N. Yıldız
SYSeray Yetkin
Seray Yetkin
GKGkamze Impraimoglou Kafaz
Gkamze Impraimoglou Kafaz
BSBurcu Sengez
Burcu Sengez
HAHani Alotaibi
Hani Alotaibi

9 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TBTugce batur
Tugce batur
EBEzgi Batu
Ezgi Batu
MSMiray Sevinin
Miray Sevinin
EZEce Şule Zangur
Ece Şule Zangur
IYİnci Yaprak
İnci Yaprak
UOUgur Ozbek
Ugur Ozbek
Neuroblastoma (NB) is the most common extracranial solid tumor in children, accounting for approximately 15% of all pediatric cancer-related deaths. While clinical staging systems provide a foundation for therapeutic decision-making, they fail to fully capture the complex interplay of genetic alterations, oncogenic signaling pathways, tumor microenvironmental dynamics, and developmental biology that collectively shape NB progression. Genomic profiling has identified recurrent driver events, including MYCN amplification, ALK mutations, ATRX and TERT dysregulation, and segmental chromosomal aberrations, which contribute to tumor aggressiveness, treatment resistance, and telomere maintenance mechanisms. Emerging therapeutic strategies are increasingly designed to target these molecular and cellular vulnerabilities. Ongoing clinical trials are evaluating ALK inhibitors, anti-GD2 antibodies, CAR-T cell therapies, and agents directed against NTRK, ROS1, KRAS, EGFR, and B7-H3, reflecting a paradigm shift toward precision medicine in NB. In this review, we provide a comprehensive overview of NB, encompassing classification systems, genetic and molecular pathogenesis, microenvironmental contributions, mechanisms of spontaneous regression, and current treatment strategies, which frame the rationale for novel, biology-driven clinical interventions.